Bisoprolol Drug Asset Due Diligence Report 2026

This Bisoprolol Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

128

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Bisoprolol can convert its Small molecule drug profile and β1-adrenergic receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Bisoprolol (query alias: bisoprolol)
Modality / target	Small molecule drug; β1-adrenergic receptor; β1-adrenergic receptor antagonists
Highest global status	Approved
Originator	TOA Eiyo Ltd., Nitto Denko Corp.
Active developers	TOA Eiyo Ltd., Nitto Denko Corp.

The MCP disease footprint includes Atrial Fibrillation, Essential Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07103655	Phase 4	Not yet recruiting	132	Percentage change in pressure gradient during the Valsalva maneuver
NCT07327749	Phase 4	Completed	59	mean blood pressure
NCT07491718	Not Applicable	Recruiting	100	Left ventricular myocardial manganese uptake.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial

Phase 3; n=280; evaluation: Negative. Reported fields: AE = The most common adverse events were COPD exacerbations, occuring in 83 (58%) participants in the bisoprolol group and 87 (64%) in the placebo group. ; AE = The most common adverse events were COPD exacerbations, occuring in 83 (58%) participants in the bisoprolol group and 87 (64%) in the placebo group.

Effect of Digoxin vs Beta-Blockers on Left Atrial Strain for Heart Rate-Controlled Atrial Fibrillation: The DIGOBET-AF Randomized Clinical Trial

Phase 3; n=60; evaluation: Positive. Reported fields: Peak LAS = 5.9 % ( 3.4); Peak LAS = 7.5 % ( 3.2)

Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.

Phase 4; n=5020; evaluation: Negative. Reported fields: Composite endpoint = 208 Pts ; Composite endpoint = 199 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Bisoprolol addresses Atrial Fibrillation, Essential Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-11-05	Daewoong to sell Merck's cardiovascular disease treatment	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition of arni and bisoprolol or salt thereof, and use thereof”. The milestone feed surfaced a patent-application signal described as “One-time detection method for bisoprolol and hydrochlorothiazide tablet related substances”. The milestone feed surfaced a patent-application signal described as “Simple method for the preparation of pure bisoprolol hemihemifumarate and its intemediates”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO